Company Overview and News
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
YUM AROC TCAP HYRE ABT CRM BXS BHC CHFC RGA CSCO TBIO UXIN CAH PKD MS HSY GWP SNAP NCMI FOX JCOM HOMB AMC GILD MNLO UTX SYF MDT CYS EXPE ACB GWPH EMHTF JNJ ALV VZ APHQF VNE LMT FB RF.PRB OLED RF.PRA STIM WFC.PRL NFLX WFC.PRJ BAX EHC SKX BAC WFC.PRT ZION OKE.WI WFC.PRR WFC.PRQ WFC.PRP WFC.PRO CYS.PRA CL WFC.PRN CYS.PRB FPBK TCCB OKE WFC.PRY TCCA INTC WFC.PRX WFC.PRW AGS WFC.PRV CBS UL WYNN EVER MA GSK FNSR TCDA UA FFKT NTGN HAS FNKO SBUX CAKE APTV TXN TBQBF XOM ACBFF TWX UAA MS.PRE RF RDI MS.PRF MS.PRG IMAX CNK MS.PRA GTES AMZN TWTR HMNY TWO EBAY BBT ARMO BAC CMA EYEN CRON BV TCC MDLZ CMG PFS MS.PRI BJ GOOGL MS.PRK LVS QCOM FOXA PFE LOVE WFCNP HAL PM HRB WWW GPC PYPL PAGS DLPH MCS PFG TWMJF RDIB AMCX WEED ACN DIS MCD ABT WFC WFC.WS QRVO MJN F SLDB BRY CMCSA K CGC SNPS EMH T MRK CVX FTSV SNE LITE MEDFF PZZA TILE
Exceptional asset sensitivity and loan growth are generating strong revenue and operating income growth for this Texas-based commercial lender.
WFC WFCNP WFC.WS CMA TCBI WFC.PRL TCBIL WFC.PRJ WFC.PRT WFC.PRR TCBIW WFC.PRQ WFC.PRP WFC.PRO TCBIP WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV
State Street’s (STT - Free Report) second-quarter 2018 adjusted earnings of $2.05 per share outpaced the Zacks Consensus Estimate of $2.01. Results excluded $77 million or 17 cents per share of repositioning charge related to organizational realignment. State Street’s shares lost more than 5% in pre-market trading. Suspension of share buybacks till the end of this year due to the announcement of deal to acquire Charles River Development (“CRD”) is perhaps the primary reason.
BBT STT STT.PRC CMA STT.PRE STT.PRD STT.PRG KEY
SunTrust Banks' (STI - Free Report) second-quarter 2018 earnings of $1.49 per share outpaced the Zacks Consensus Estimate of $1.30. Also, the figure compared favorably with the prior-year quarter’s earnings of $1.03. Results were primarily driven by rise in revenues as well as lower provisions. Also, an improvement in overall asset quality was a tailwind. However, higher expenses hurt results to some extent.
STI.WS.B STI.WS.A C CMA PNC.PRP PNC.PRQ PNCFO PNC.WS STI PNC STI-A PNUCL STI.PRE
KeyCorp’s (KEY - Free Report) second-quarter 2018 earnings of 44 cents per share surpassed the Zacks Consensus Estimate of 42 cents. Also, this compared favorably with earnings of 36 cents recorded in the prior-year quarter. Shares of KeyCorp have gained almost 2% in pre-market trading. Notably, the stock’s price performance after the full day’s trading will give a better indication about investors’ sentiments.
STI.WS.B STI.WS.A STI CMA STI-A STI.PRE KEY
First Horizon's second quarter results were roundly disappointing, with weaker core interest income, very weak trading results, and higher than expected expenses.
WFC WFCNP WFC.WS CMA WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV
BancorpSouth (BXS - Free Report) reported second-quarter 2018 operating earnings of 56 cents per share, beating the Zacks Consensus Estimate by a penny. Also, the bottom line compared favorably with the year-ago quarter earnings of 41 cents.
CMA FHN FHN.PRA BXS
BB&T Corporation’s (BBT - Free Report) second-quarter 2018 adjusted earnings of $1.01 was in-line with the Zacks Consensus Estimate. Moreover, the figure recorded 29.5% surge from the year-ago quarter. Results reflected slight rise in revenues and lower operating expenses. Also, the balance sheet position remained strong during the quarter under review. Further, stable provisions supported results to some extent.
BBT PNC.WS C CMA PNC.PRP PNC PNC.PRQ PNUCL PNCFO
Comerica once again delivered strong NIM leverage even though loan and balance sheet growth remain lackluster.
WFC WFCNP WFC.WS CMA WFC.PRL WFC.PRJ WFC.PRT OZK WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV
PNC posts a modest beat in the second quarter, with a Goldilocks combination of loan growth, spread improvement, and cost leverage.
WFC WFCNP WFC.WS CMA WFC.PRL WFC.PRJ BAC WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV
The earnings season is knocking at the door and investors are keen to see how major banks have performed in the second quarter amid uncertainty related to the trade war fears.
STI.WS.B STI.WS.A STI JPM CMA STI-A MTB STI.PRE KEY
Good morning. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Comerica Second Quarter 2018 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions].
CMA.WS DB MS.PRI CMA MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA CMPWW
Comerica (CMA - Free Report) reported adjusted earnings per share of $1.90 in second-quarter 2018, up from the year-ago adjusted figure of $1.15. Including certain non-recurring items, earnings came in at $1.87. The Zacks Consensus Estimate was $1.62.
WFC WFCNP WFC.WS C CMA WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY 3772 WFC.PRX WFC.PRW WFC.PRV
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to CMA / Comerica, Inc. on message board site Silicon Investor.
as of ET